Completed PHASE2 INTERVENTIONAL 3-arm NCT01336322

Metformin and Sitagliptin in Women With Previous Gestational Diabetes

Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Women With Previous Gestational Diabetes

Sponsor: Merck Sharp & Dohme LLC

Conditions Pre-diabetes

Interventions Metformin Sitagliptin Sitagliptin + Metformin

Updated 11 times since 2017 Last updated: Mar 21, 2019 Started: May 31, 2011 Primary completion: Dec 31, 2017 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01336322, this PHASE2 trial focuses on Pre-diabetes and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 11 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2022 [monthly]

Completed PHASE2
Apr 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 6 earlier versions

Nov 2018 — Apr 2019 [monthly]

Recruiting PHASE2
Jul 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Unknown Status → Recruiting
Feb 2017 — Feb 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
University of Pisa

Data source: University of Pisa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pisa, Italy